French Agency sets up reagent working groups:
This article was originally published in Clinica
The French Agence du Medicament has set up three working groups to study diagnostic reagents. The first will be concerned with reagents for infectious disease detection; the second is for testing and confirmation of retrovirus and viral hepatitis; the third will concern molecular biological reagents used in infectious diseases. The groups have a three-year mandate, according to the French Official journal (September 28th, 1995).
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.